The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Rethinking drug development for early-phase biotech companies
A practical guide to building smarter early-phase development strategies and avoiding costly delays
Early-stage biotechs are increasingly driving innovation, yet many operate with development models not built for today’s landscape. As a growing share of drug approvals comes from organizations without prior commercialization experience, success now depends not only on scientific ambition but also on making high-stakes development decisions early—often before IND submission—when downstream implications are not fully visible. These early choices can determine a program’s long-term success.
How can biotechs reframe drug development decisions?
This white paper examines how these biotech companies can:
- Reframe early development decisions to reduce downstream risk
- Identify where early complexity undermines momentum
- Evaluate connected development approaches for long-term value
It also explores why more early-stage companies are turning to integrated, end-to-end development strategies that bring CDMO, CRO, and clinical supply capabilities together within a single framework—such as Thermo Fisher Scientific’s Accelerator™ Drug Development model.
